Annogen

About Annogen

Bespoke promoters and enhancers, for any tissue, any organism.

At Annogen, our vision is a future where safe and effective advanced therapies are specifically expressed in the right tissues with no off-target effects. We believe that this can be achieved by bespoke promoters (genetic switches) and genomic expression sites.

Therefore, Annogen is on a mission towards becoming the leading expertise center for gene expression engineering in order to improve the safety and effectiveness of tomorrow's cell and gene therapies.

Annogen leverages its proprietary SuRE™ technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression for gene & cell therapy, as well as for recombinant protein and virus production. In addition, we develop service projects based on our proprietary AIM™ technology to identify favorable gene insertions and their expression levels for more than 100,000 integrations in parallel. These approaches typically enable big improvements in any biomedical strategy involving the (over-) expression of genes.

Annogen was founded in 2017 by Dr. Joris van Arensbergen, who developed and published the SuRE™ technology as a post-doctoral fellow in the laboratory of Prof. Dr. Bas van Steensel at the world-renowned Netherlands Cancer Institute (NKI). Today, Annogen is the trusted partner for bespoke gene expression engineering for leading biopharmaceutical, agricultural and academic research centers globally.

Keywords

• Capsid Screening
• Cell Therapy
• Crop Engineering
• Gene Editing
• Gene Expression
• Gene Promoters
• Gene Therapy
• Genomics
• Mpra
• Promoters
• Safe Harbor Loci
• Synthetic Biology
• Synthetic Promoters
• Viral Vectors

Address

• Headquarters

  Science Park 4061098XH AmsterdamNoord-Holland, Netherlands

Team by function

Based on 9 public job profiles as of 3 September 2026.

• Research / R&D3
• Other / Unclassifiable2
• Consulting / Advisory1
• Executive / C-Suite1
• Healthcare / Medical1
• Skilled Trades / Technical1